SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 52-Week High – Here’s Why

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) reached a new 52-week high during trading on Tuesday . The stock traded as high as $3.59 and last traded at $3.6690, with a volume of 1201527 shares trading hands. The stock had previously closed at $3.35.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, SELLAS Life Sciences Group has a consensus rating of “Hold” and a consensus target price of $7.00.

SELLAS Life Sciences Group Stock Up 13.1%

The stock has a 50-day moving average price of $1.89 and a 200 day moving average price of $1.84. The firm has a market capitalization of $539.85 million, a price-to-earnings ratio of -13.54 and a beta of 2.51.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. As a group, equities analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.

Insider Activity at SELLAS Life Sciences Group

In other news, Director Katherine Bach Kalin bought 63,400 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average price of $1.59 per share, with a total value of $100,806.00. Following the completion of the purchase, the director directly owned 104,400 shares of the company’s stock, valued at $165,996. This represents a 154.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Institutional investors have recently made changes to their positions in the business. Axxcess Wealth Management LLC acquired a new position in shares of SELLAS Life Sciences Group in the third quarter valued at $26,000. BNP Paribas Financial Markets raised its holdings in SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after acquiring an additional 9,299 shares in the last quarter. Blair William & Co. IL bought a new stake in SELLAS Life Sciences Group in the second quarter valued at approximately $35,000. ProShare Advisors LLC acquired a new position in shares of SELLAS Life Sciences Group in the second quarter valued at approximately $43,000. Finally, Sei Investments Co. acquired a new position in SELLAS Life Sciences Group in the 3rd quarter valued at $43,000. 17.38% of the stock is currently owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.